Benitec Biopharma Inc. (BNTC) Stock Forecast
BNTC analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.86 / 5 from 7 analysts
- Price target
- $24.33 average of analyst targets
- Upside to target
- +200.0% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.28
- 52-week range
- $8.11 – $16.52
BNTC analyst ratings
7 analystsNumber of analysts at each rating.
BNTC price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BNTC earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.28 | −$0.30 | −$0.26 | −$0.22 | −26.4% | 5 |
| Next quarter (Dec '26) | −$0.29 | −$0.32 | −$0.26 | −$0.26 | −11.5% | 5 |
| Current fiscal year (FY2027) | −$1.18 | −$1.34 | −$1.06 | −$0.98 | −20.2% | 6 |
| Next fiscal year (FY2028) | −$1.32 | −$1.45 | −$1.20 | −$1.18 | −12.4% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BNTC revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 5 |
| Next quarter (Dec '26) | $0 | $0 | $0 | 0.0% | 5 |
| Current fiscal year (FY2027) | $0 | $0 | $0 | 0.0% | 6 |
| Next fiscal year (FY2028) | $0 | $0 | $0 | 0.0% | 3 |
BNTC EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BNTC EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.28 | −$0.28 | −$0.28 | −$0.28 | −$0.28 | −0.7% | 1 up · 2 down |
| Next quarter (Dec '26) | −$0.30 | −$0.29 | −$0.29 | −$0.30 | −$0.29 | −2.3% | 1 up · 1 down |
| Current fiscal year (FY2027) | −$1.15 | −$1.11 | −$1.12 | −$1.20 | −$1.18 | +2.8% | 0 up · 3 down |
| Next fiscal year (FY2028) | −$1.21 | −$0.77 | −$1.19 | −$1.32 | −$1.32 | +9.5% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BNTC earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BNTC beat in 6 of 12.
What analysts expect from BNTC
7 analysts cover Benitec Biopharma; their consensus rating is strong buy (4.86 on a 1–5 scale, where 5 is a strong buy). The average price target is $24.33, 200.0% above the latest close of $8.11. Analysts expect earnings of −$1.18 per share for FY2027, −20.2% from a year earlier. For FY2028 the average estimate is −$1.32 per share. Benitec Biopharma beat the EPS estimate in 6 of the last 12 quarters.
Related: BNTC income statement, BNTC key metrics, BNTC chart. See the BNTC stock overview for the latest quote and news.
BNTC forecast FAQ
What is Benitec Biopharma's price target?
The average analyst price target for Benitec Biopharma is $24.33, 200.0% above the latest close of $8.11.
Is Benitec Biopharma a buy, hold or sell?
Of 7 analysts covering Benitec Biopharma, 6 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Benitec Biopharma's EPS forecast?
Analysts forecast −$1.18 per share for FY2027 (range −$1.34 to −$1.06); for FY2028 the estimate is −$1.32.
When does Benitec Biopharma report earnings?
Benitec Biopharma is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.28.
Does Benitec Biopharma usually beat earnings estimates?
Benitec Biopharma reported EPS at or above the analyst estimate in 6 of the last 12 quarters.